Breaking News
0

J&J Earnings: No News Is Good News Until Cancer Claims Are Settled

By Investing.com (Haris Anwar/Investing.com)Stock MarketsJul 15, 2019 02:34AM ET
www.investing.com/analysis/jj-earnings-no-news-is-good-news-until-cancer-claims-are-settled-200439549
J&J Earnings: No News Is Good News Until Cancer Claims Are Settled
By Investing.com (Haris Anwar/Investing.com)   |  Jul 15, 2019 02:34AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

* Reports Q2 2019 results on Tuesday, July 16, before market open
* Revenue Expectation: $20.29 billion
* EPS Expectation: $2.44

For Johnson & Johnson (NYSE:JNJ) investors no news is good news until the world’s largest maker of both consumer and pharmaceutical health care products finds a way to settle thousands of lawsuits claiming its talcum powder caused ovarian cancer.

There are so many of these cases—14,000 according to media estimates—that the issue threatens enormous financial and reputational risks to the multinational pharmaceutical company. The stock plunged more than 4% on Friday after reports the U.S. Justice Department is investigating whether the company has withheld from the public the possible cancerous risks of its talcum powder.

The criminal probe coincides with a regulatory investigation and civil claims by thousands of cancer patients that J&J’s Baby Powder talc was responsible for their illness. Now, a grand jury in Washington is examining documents that could help shed light onto what officials from the company may have known about any carcinogens in its products, a Bloomberg report said citing unnamed sources.

These developments and ongoing litigations in multiple jurisdictions have kept JNJ shares under pressure since December last year, despite some positive news on the earnings front. Trading at $134.29 at Friday's close, J&J stock is up just 5.5% this year, underperforming the S&P 500, which surged more than 20% in the same period.

J&J price chart
J&J price chart

For the quarter that ended on June 30, the company is expected to earn $2.44 a share on sales of $20.9 billion, according to analysts’ consensus estimate. Though baby powder accounts for only a tiny fraction of J&J’s annual revenue, it’s been a core brand for the company for more than a century—as well as a big drag on the company’s financial health amid uncertainty about the amount it may need to set aside for out-of-court settlements.

The company has said it has set aside money for legal costs related to talc claims but hasn’t specified the amount. According to Bloomberg estimates civil settlements could cost J&J as much as $15 billion overall. The company, however, maintains that it has no liability because its products are safe.

J&J Earnings Strength

Keeping the lawsuits-related risk aside, J&J has consistently proven that its product portfolio is strong enough to produce hefty cash flows for investors. In the first quarter, the company's fast-growing pharmaceutical unit was key to offsetting its weaker consumer and medical device lines.

J&J’s drug business is now the largest of the company’s three main segments, with Q1 sales growing 4.1% to $10.2 billion—helped by psoriasis drug Stelara, sales of which were up 32% to $1.4 billion.

Another bright spot was the launch of nasal spray Spravato, a close chemical cousin of the anaesthetic ketamine that works quickly to alleviate symptoms of depression. The rollout is “off to a very, very strong start,” Jennifer Taubert, head of the group's pharmaceutical unit, told investors on a conference call.

Bottom Line

J&J stock could remain under pressure for some time and it’s hard to see it hitting a bottom anytime soon. At the same time, we continue to believe that the company has the resources to fight these claims, thanks to its wide moat and massive cash-generation capabilities. But the question is: when should investors focus on the company’s core earnings and start ignoring litigation-related risks?

In our view, it all depends on how consistently J&J performs on the earnings front and whether it shows its future outlook is improving. The Q2 earnings report coming out tomorrow should give some clarity.

J&J Earnings: No News Is Good News Until Cancer Claims Are Settled
 

Related Articles

J&J Earnings: No News Is Good News Until Cancer Claims Are Settled

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email